Inovio Pharmaceuticals Inc. (INO)

2.31
0.13 5.33
NASDAQ : Health Technology
Prev Close 2.44
Open 2.39
Day Low/High 2.20 / 2.39
52 Wk Low/High 1.92 / 5.47
Volume 1.20M
Avg Volume 612.30K
Exchange NASDAQ
Shares Outstanding 99.03M
Market Cap 242.62M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

We added to one name during a stellar week for the majority of the portfolio.

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

Inovio's Positive Zika Vaccine Clinical Study Data Published In New England Journal Of Medicine

Inovio's Positive Zika Vaccine Clinical Study Data Published In New England Journal Of Medicine

Phase 1 results show GLS-5700 induced high levels of antibodies in 100% of participants; Serum from vaccinated subjects prevented infection in virus challenge in animals

Stocks Under $10 Weekly Summary

We took a healthy profit trimming one name and added to three other positions last week.

Stocks Under $10 Weekly Summary

We added a digital security name to the Bullpen during a mixed week for the portfolio.

Inovio DMAb™ Constructs Shrink Prostate Tumors And Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies

Inovio DMAb™ Constructs Shrink Prostate Tumors And Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies

Inovio's DNA-based Monoclonal Antibody Programs Boosted by Scientific Publications

First Week Of May 2018 Options Trading For Inovio Pharmaceuticals (INO)

First Week Of May 2018 Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the May 2018 expiration.

Stocks Under $10 Weekly Summary

We initiated 2 new positions and jettisoned another over the last week.

Inovio And Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection

Inovio And Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection

Korean trial is fully funded by partners and will evaluate Inovio's advanced intradermal delivery system

An Update on the Dog of the Portfolio

I don't like egg on my face. That said, I love a good fight.

Stocks Under $10 Weekly Summary

We remain cautious during this historically volatile month for the market.

Inovio's Cancer Immunotherapy (INO-5150) Slowed PSA Rise And Significantly Increased PSA Doubling Times In Patients With Recurrent Prostate Cancer

Inovio's Cancer Immunotherapy (INO-5150) Slowed PSA Rise And Significantly Increased PSA Doubling Times In Patients With Recurrent Prostate Cancer

INO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study

Stocks Under $10 Weekly Summary

We scaled into one position during a week dominated by Hurricane Harvey and its aftermath.

Adding to a Pharma Position

We will keep fighting small battles until this stock has paid us back.

Stocks Under $10 Weekly Summary

We initiated 2 small positions last week as the market moved higher.

First Week of INO October 20th Options Trading

First Week of INO October 20th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the October 20th expiration.

Stocks Under $10 Weekly Summary

We used last week's weakness to scale into several positions.

RSI Alert: Inovio Pharmaceuticals (INO) Now Oversold

RSI Alert: Inovio Pharmaceuticals (INO) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Adding to Inovio and Pixelworks on Today's Weakness

I will leave both INO and PXLW short of what I consider to be full positions.

Adding an Industrial Play to the Bullpen

Energy Recovery has been going wrong all year; but it has potential.

Stocks Under $10 Weekly Summary

North Korea puts a worrying wrinkle in the markets. We add to 2 portfolio positions.

Inovio Earnings Don't Look So Good Under the Hood

Expenses rose, revenue was bloated by a deferred lump sum and cash and equivalents has declined.

Inovio Pharmaceuticals Stock Sees Short Interest Drop 20.5%

Inovio Pharmaceuticals Stock Sees Short Interest Drop 20.5%

The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,217,694 share decrease in total short interest for Inovio Pharmaceuticals Inc. , to 8,603,835, a decrease of 20.49% since 07/14/2017.

Antares and Amplify Brands Reports; Plus Other Earnings News

Five portfolio names report today. Here is what we have seen, and what two expect after the closing bell.

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

What are the chances of a Draghi dovish surprise? I wouldn't bet the farm on anything.

Stocks Under $10 Weekly Summary

It was a rough week for the portfolio.

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

Jim Cramer is bullish on Chevron, Universal Display, Dynavax Technologies, and Schlumberger.

TheStreet Quant Rating: D- (Sell)